Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Tumour Diagnosis and Prognosis by New MRI Contrast Agents
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1343
Breast cancer is the second most commonly diagnosed cancer among U.S. women, with a 13% incidence. The use of screening tests for early detection of breast cancer and...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Breast cancer is the second most commonly diagnosed cancer among U.S. women, with a 13% incidence. The use of screening tests for early detection of breast cancer and other cancers provides better opportunities for patients to survive these cancers, with fewer side effects. Oestrogen receptor (ER) is a well-established marker of breast cancer, and therefore the capacity to map this receptor may indicate high risk for cancer development. Current clinical methods that measure ER are subjective and semi-quantitative, or suffer from low target to non-target tissue image contrast. Hence, an accurate, standardized in vivo method to determine ER level would highly improve patient's care.

Aims/Hypothesis

There is a need for a non-invasive method to diagnose breast cancer.

Research

Cancers such as breast and prostate cancer most frequently express the steroid receptors of their origin and can accumulate molecules that have high binding affinities for the receptors, namely, receptor ligands. In the outlined technology, new MRI sensitive ligands that bind specifically to the oestrogen receptor were synthesized, in order to identify the presence of the receptors by non-invasive MRI methods. These probes can map the oestrogen receptor in vivo using contrast enhanced MRI.

Conclusion

The present invention allows for the identification of ER by specific MRI contrast agents.

Relevance/Opportunity

Please enquire regarding licensing or codevelopment partnerships quoting reference no. 1343.
FEATURED
Last Updated May 2015
Technology Type DIAGNOSTIC
Phase of Development PRECLINICAL
CORPORATION